Skip to main content
padlock icon - secure page this page is secure

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Buy Article:

$59.00 + tax (Refund Policy)

The role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: JAK inhibitor; JAK2; allogeneic transplantation; calreticuline; intent‐to‐treat analysis; myeloproliferative leukemia virus; primary myelofibrosis; secondary myelofibrosis

Document Type: Research Article

Publication date: July 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more